# AMNOG Knowledge Graph
> 2186 assessments, 1415 subgroup ratings (Fragestellungen), structured and searchable.

## About
This site provides structured access to IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) benefit assessments under §35a SGB V (AMNOG). IQWiG assesses the added benefit of new drugs compared to an appropriate comparator therapy (Zweckmäßige Vergleichstherapie / ZVT). The G-BA (Gemeinsamer Bundesausschuss) then makes the final benefit decision.

## Base URL
https://iqwig.shoulde.rs

## Machine-readable endpoints

GET /api/stats
Returns: assessment_count, rated_count, endpoint_count, dispute_count, study_count, rejected_count, rating_distribution (by ausmaß), by_area, by_year, recent

GET /api/assessments?area=&ausmaß=&year=&type=&search=&page=
Returns: paginated list of assessments with benefit rating summaries
Filters: area (therapeutic area), ausmaß (major|considerable|minor|non_quantifiable|none|less), year (YYYY), type (initial|addendum|reassessment)

GET /api/assessments/{id}
Returns: full assessment with fragestellungen[], endpoint_assessments[], methodological_disputes[], included_studies[], rejected_evidence[], documents[], related[]
Example: /api/assessments/A25-160

GET /api/search?q={query}&limit={n}
Full-text search across assessment corpus. Returns passages with assessment metadata.

GET /llms-full.txt
Full index of all 2186 assessments with IDs, drug names, and rating summaries.

## Benefit Rating Scale (benefit_ausmaß)
- major: Erheblicher Zusatznutzen — major added benefit
- considerable: Beträchtlicher Zusatznutzen — considerable added benefit
- minor: Geringer Zusatznutzen — minor added benefit
- non_quantifiable: Nicht quantifizierbarer Zusatznutzen — non-quantifiable added benefit
- none: Kein Zusatznutzen — no added benefit (most common)
- less: Geringerer Nutzen — worse than comparator

## Probability of Benefit (benefit_wahrscheinlichkeit)
- proof: Beleg — proof (RCT data)
- indication: Hinweis — indication (observational/indirect)
- hint: Anhaltspunkt — hint (limited data)

## Therapeutic Areas
- Cancer: 733 assessments
- Digestion, metabolism and hormones: 247 assessments
- Head and nerves: 147 assessments
- Immune system and infections: 144 assessments
- Heart and circulation: 117 assessments
- Haematology: 101 assessments
- Airways and respiratory system: 94 assessments
- Muscles, bones and joints: 91 assessments
- Skin and hair: 85 assessments
- DMP and clinical pratice guidelines: 50 assessments
- Oncology: 39 assessments
- Children's and adolescents' health: 32 assessments
- Kidneys and urinary system: 32 assessments
- Reproductive health and birth: 32 assessments
- Prevention and screening: 30 assessments
- Surgery: 22 assessments
- Mental and emotional wellbeing: 18 assessments
- Oncology / Haematology: 16 assessments
- Diagnostics: 8 assessments
- Onkologie: 6 assessments
- Teeth: 6 assessments
- Infectious diseases: 5 assessments
- Cardiology: 3 assessments
- Cystic Fibrosis: 3 assessments
- Cystic fibrosis: 3 assessments
- Diabetes mellitus Typ 2: 3 assessments
- Neurology: 3 assessments
- Respiratory: 3 assessments
- oncology: 3 assessments
- Endocrinology / Diabetes: 2 assessments
- Endocrinology / Metabolism: 2 assessments
- Infektiologie: 2 assessments
- Mammakarzinom: 2 assessments
- Ophthalmology: 2 assessments
- Respiratory diseases: 2 assessments
- Rheumatology: 2 assessments
- Allergology: 1 assessments
- Cardiovascular diseases: 1 assessments
- Dermatology: 1 assessments
- Diabetes mellitus Typ 2 bei Kindern und Jugendlichen: 1 assessments
- Endocrinology / Metabolic diseases: 1 assessments
- Gastroenterology: 1 assessments
- HIV infection: 1 assessments
- HIV-Infektion bei Jugendlichen: 1 assessments
- Hepatitis C – chronic: 1 assessments
- Hypertension: 1 assessments
- Infectious Diseases / Paediatrics: 1 assessments
- Infectious diseases / HIV: 1 assessments
- Kardiologie: 1 assessments
- Narkolepsie: 1 assessments
- Neurology / Rare diseases: 1 assessments
- Oncology / NSCLC: 1 assessments
- Oncology / Urology: 1 assessments
- Oncology/Haematology: 1 assessments
- Ophthalmologie: 1 assessments
- Psychiatry: 1 assessments
- Pulmonary Disease – Chronic Obstructive: 1 assessments
- Pulmonology: 1 assessments
- Pulmonology / Rare diseases: 1 assessments
- Rare diseases / Pulmonology: 1 assessments
- Schilddrüsenkarzinom: 1 assessments
- dermatology: 1 assessments
- diabetes mellitus: 1 assessments
- hepatitis C – chronic: 1 assessments

## Chat Interface
Ask natural language questions at /chat
- "What benefit rating did semaglutide receive for type 2 diabetes?"
- "How often does IQWiG mandate a different ZVT than the manufacturer proposed?"
- "What are the most common reasons for study rejection in oncology?"
- "Find assessments where IQWiG rejected an indirect comparison"